Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biogen Inc (NASDAQ:BIIB)

289.73
Delayed Data
As of May 31
 +6.94 / +2.45%
Today’s Change
242.07
Today|||52-Week Range
420.99
-5.43%
Year-to-Date
Icahn Bets on Allergan's Brett Saunders in Post-Pfizer Era
May 31 / TheStreet.com - Paid Partner Content
Biogen Is Looking Quite Strong
May 27 / TheStreet.com - Paid Partner Content
Roche's Subcutaneous Formulation of MabThera Gets EU Nod
May 31 / Zacks.com - Paid Partner Content
Cramer: Avoid Sloppiness by Watching Your Stock Table Manners
May 26 / TheStreet.com - Paid Partner Content
Biogen & AbbVie's Multiple Sclerosis Drug Gets FDA Nod
May 30 / Zacks.com - Paid Partner Content
Better Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals Inc.
May 24 / MotleyFool.com - Paid Partner Content
Last Week's Best Healthcare ETF
May 28 / MotleyFool.com - Paid Partner Content
The Best Buys in Biopharma Today
May 24 / MotleyFool.com - Paid Partner Content
Biogen (BIIB) Stock is the 'Chart of the Day'
May 27 / TheStreet.com - Paid Partner Content